Merck & Co., Inc. $MRK Stock Position Boosted by Aristotle Atlantic Partners LLC

Aristotle Atlantic Partners LLC lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 11.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 552,486 shares of the company’s stock after acquiring an additional 55,876 shares during the quarter. Merck & Co., Inc. comprises approximately 3.1% of Aristotle Atlantic Partners LLC’s holdings, making the stock its 7th biggest holding. Aristotle Atlantic Partners LLC’s holdings in Merck & Co., Inc. were worth $66,459,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Kingdom Financial Group LLC. purchased a new stake in Merck & Co., Inc. during the 4th quarter worth $25,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. in the 4th quarter valued at about $26,000. Prosperity Bancshares Inc acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $26,000. High Note Wealth LLC grew its stake in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $31,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $131.06 on Friday. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $131.74. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The firm has a market cap of $323.68 billion, a price-to-earnings ratio of 36.92, a PEG ratio of 5.20 and a beta of 0.19. The stock has a 50 day moving average of $121.67 and a 200-day moving average of $117.71.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s revenue was up 4.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 2.74 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced initial access plans for alimatravir, its investigational once-monthly oral HIV PrEP in Phase 3 development, and said it has signed voluntary licensing agreements covering 129 countries. That broad access strategy could support adoption in large international markets if the drug is approved. Article Title
• Neutral Sentiment: Merck also issued a company release on the same alimatravir access plan, reinforcing that the program is moving forward and that it is trying to expand availability in regions that account for most new HIV diagnoses globally. Article Title
• Neutral Sentiment: Traders also bought a high volume of Merck call options, which may reflect rising bullish speculation around the stock and the HIV pipeline, but it does not by itself change fundamentals. Article Title
• Negative Sentiment: Par Health launched the first generic version of Janumet XR in the U.S., which may pressure Merck’s diabetes-related sales and adds another competitive headwind for an established product. Article Title

Analyst Ratings Changes

MRK has been the topic of several recent analyst reports. Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Cantor Fitzgerald restated a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Bank of America lifted their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. CICC Research assumed coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Finally, Wall Street Zen cut Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $133.94.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.